No studies have yet been performed regarding hypoxia imaging and immunotherapy in NSCLC, but in HNSCC [18F]FMISO imaging was used pre-clinically in combined anti-PD-1 and anti-CTLA-4 treatment to monitor changes in the TME during treatment. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.